No Data
Amgen Is Maintained at Buy by Argus Research
Argus Research Maintains Buy on Amgen, Raises Price Target to $340
Amgen Analyst Ratings
Argus Research Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $340
Argus Research analyst Jasper Hellweg maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $310 to $340.According to TipRanks data, the analyst has a success rate of 60.5% a
Novo Nordisk, Eli Lilly Still Top 2 Pharma Stocks: Analyst
Novo-Nordisk's "miracle weight-loss drug" has been approved domestically, waiting to explode onto the multi-billion dollar market! How to capture this wave of "weight-loss fever"?
With the relentless competition among pharmaceutical research and development companies, the indications for GLP-1 are expected to continuously expand, and institutions are also constantly revising their expectations for the market size of weight-loss drugs.